Efficacy and safety of Artemisia annua sublingual immunotherapy in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons.
Allergic conjunctivitis
Allergic rhinitis
Inhaled allergen
Pollen concentration
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
21
04
2023
accepted:
14
06
2023
medline:
10
10
2023
pubmed:
27
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
This study investigates the efficacy and safety of sublingual immunotherapy (SLIT) with A. annua allergens in patients with seasonal allergic rhinoconjunctivitis over two pollen seasons. Seventy patients with moderate-severe seasonal allergic rhinoconjunctivitis were divided evenly into the SLIT and control groups. The SLIT last from 3 months before the summer-autumn pollen season in 2021 till the end of the summer-autumn pollen season in 2022. The daily individual symptom score, total rhinoconjunctivitis symptom score (dTRSS), total medication score (dTMS), combined score of medication and rhinoconjunctivitis symptom (dCSMRS), visual analog scale (VAS) score, and adverse events (AEs) were evaluated. The average pollen concentration in 2022 was twice that previous two-year during the pollen season. Fifty-six patients completed treatments (SLIT group: 29, control group: 27). Compared with baseline, the individual symptoms, dTRSS, dTMS, dCSMRS, and VAS scores of SLIT group declined in 2021. After 16 months of SLIT, all efficacy indexes in 2022 were still lower than baseline and equivalent to those in 2021. In control group, the efficacy indexes in 2022 were higher than that in 2020 and 2021. The efficacy indexes of SLIT group were lower than those of control group in 2021 and 2022. SLIT is effective for both mono- and poly-sensitized patients. AEs incidence in SLIT group was 82.7% without severe AEs. The A. annua-SLIT can obtain efficacy and safety over two pollen seasons for patients with moderate-severe seasonal allergic rhinoconjunctivitis.
Identifiants
pubmed: 37365351
doi: 10.1007/s00405-023-08078-7
pii: 10.1007/s00405-023-08078-7
doi:
Substances chimiques
Allergens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4939-4947Subventions
Organisme : Key Research and Development Projects of Shaanxi Province
ID : 2020SF-020
Organisme : First Affiliated Hospital of Zhengzhou University
ID : XJTU1AF-CRF-2022-022
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of allergic rhinitis (2022, revision). Chin J Otorhinolaryngol Head Neck Surg, 2022,57(02):106–129
Deng ZY, Liu XJ, Sa RN et al (2021) Epidemiological investigation of allergic rhinitis in central cities and countrysides of Inner Mongolia region. Chin J Otorhinolaryngol Head Neck Surg 56(06):635–642
Gotoh M, Yonekura S, Imai T et al (2019) Long-term efficacy and dose-finding trial of Japanese cedar pollen SLIT tablet. J Allergy Clin Immunol Pract 7(4):1287-1297.e8. https://doi.org/10.1016/j.jaip.2018.11.044
doi: 10.1016/j.jaip.2018.11.044
pubmed: 30537561
Wang XY, Ma TT, Wang XY et al (2018) Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of northern China. Allergy 73(6):1232–1243
doi: 10.1111/all.13388
pubmed: 29322523
Roberts G, Pfaar O, Akdis CA et al (2018) EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy 73(4):765–798
doi: 10.1111/all.13317
pubmed: 28940458
Li H, Chen S, Cheng L et al (2019) Chinese guideline on sublingual immunotherapy for allergic rhinitis and asthma. J Thorac Dis 11(12):4936
doi: 10.21037/jtd.2019.12.37
pubmed: 32030209
pmcid: 6988076
Halken S, Larenas-Linnemann D, Roberts G et al (2017) EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol 28(8):728–745
doi: 10.1111/pai.12807
pubmed: 28902467
Liu X, Ng CL, Wang DY (2018) The efficacy of sublingual immunotherapy for allergic diseases in Asia. Allergol Int 67(3):309–319
doi: 10.1016/j.alit.2018.02.007
pubmed: 29551278
Cheng L, Zhou WC (2019) Sublingual immunotherapy of house dust mite respiratory allergy in China. Allergol Immunopathol (Madr) 47(1):85–89
doi: 10.1016/j.aller.2018.02.008
pubmed: 29921463
Lou H, Wang X, Wei Q et al (2020) Artemisia Annua sublingual immunotherapy for seasonal allergic rhinitis: A multicenter, randomized trial. World Allergy Organ J 13(9):100458
doi: 10.1016/j.waojou.2020.100458
pubmed: 32963688
pmcid: 7490724
Leonardi A, Castegnaro A, Valerio ALG et al (2015) Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population-based study. Curr Opin Allergy Clin Immunol 15(5):482–488
doi: 10.1097/ACI.0000000000000204
pubmed: 26258920
Lou H, Ma S, Zhao Y et al (2017) Sensitization patterns and minimum screening panels for aeroallergens in self-reported allergic rhinitis in China. Sci Rep 7(1):9286
doi: 10.1038/s41598-017-10111-9
pubmed: 28839248
pmcid: 5570894
Gao Z, Fu WY, Sun Y et al (2019) Artemisia pollen allergy in China: Component-resolved diagnosis reveals allergic asthma patients have significant multiple allergen sensitization. Allergy 74(2):284–293
doi: 10.1111/all.13597
pubmed: 30155917
Lou H, Huang Y, Ouyang Y et al (2020) Artemisia annua -sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial. Allergy 75(8):2026–2036
doi: 10.1111/all.14218
pubmed: 32030780
Yang J, Shen Z, Liu L et al (2022) Clinical efficacy and safety of Artesimia annua-sublingual immunotherapy in seasonal allergic rhinitis patients based on different intervention time. Int Arch Allergy Immunol 183(8):852–859
doi: 10.1159/000524108
pubmed: 35413714
Okubo K, Kurono Y, Fujieda S et al (2011) Japanese guideline for allergic rhinitis. Allergol Int 60(2):171–189
doi: 10.2332/allergolint.11-RAI-0334
pubmed: 21636965
Ouyang YH, Zhao LP, Zhang L (2013) Relationship of pollinosis onset patterns and atmospheric pollen species and concentration. Journal of Capital Medical University 34(06):805–807
Prince A, Norris MR, Bielory L (2018) Seasonal ocular allergy and pollen counts. Curr Opin Allergy Clin Immunol 18(5):387–392
doi: 10.1097/ACI.0000000000000475
pubmed: 30020257
Takamura E, Uchio E, Ebihara N et al (2017) Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int 66(2):220–229
doi: 10.1016/j.alit.2016.12.004
pubmed: 28209324
Pfaar O, Bastl K, Berger U et al (2017) Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis - an EAACI position paper. Allergy 72(5):713–722
doi: 10.1111/all.13092
pubmed: 27874202
Zuberbier T, Bachert C, Bousquet PJ et al (2010) GA
doi: 10.1111/j.1398-9995.2010.02474.x
pubmed: 21039596
Brożek JL, Bousquet J, Baena-Cagnani CE et al (2010) Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol 126(3):466–476
doi: 10.1016/j.jaci.2010.06.047
pubmed: 20816182
Wang XD, Zheng M, Lou HF et al (2016) An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy 71(8):1170–1180
doi: 10.1111/all.12874
pubmed: 26948849
Meng J, Xu R, Ye J et al (2022) Expert consensus on classification and diagnosis of allergic rhinitis(2022, Chengdu). Chin J Ophthalmol and Otorhinolaryngol 22(3):10
Creticos PS, Esch RE, Couroux P et al (2014) Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 133(3):751–758
doi: 10.1016/j.jaci.2013.10.041
pubmed: 24332263
Jerzynska J, Stelmach W, Majak P et al (2018) Comparison of the effect of 5-grass pollen sublingual immunotherapy tablets and drops in children with rhinoconjunctivitis. Allergy Asthma Proc 39(1):66–73
doi: 10.2500/aap.2018.39.4099
pubmed: 29279062
Okamoto Y, Okubo K, Yonekura S et al (2015) Efficacy and safety of sublingual immunotherapy for two seasons in patients with japanese cedar pollinosis. Int Arch Allergy Immunol 166(3):177–188
doi: 10.1159/000381059
pubmed: 25895909
San Nicoló M, Högerle C, Gellrich D et al (2021) Relevance of major allergens in weed pollen allergy. Int Arch Allergy Immunol 182(7):637–641
doi: 10.1159/000514719
pubmed: 33839729
Dai L, Liu J, Zhao Q et al (2022) Investigation of allergic sensitizations in children with allergic rhinitis and/or asthma. Front Pediatr 10:842293
doi: 10.3389/fped.2022.842293
pubmed: 35372139
pmcid: 8964996
Nelson H, Blaiss M, Nolte H et al (2013) Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy 68(2):252–255
doi: 10.1111/all.12074
pubmed: 23205670
Thomas WR (2010) Geography of house dust mite allergens. Asian Pac J Allergy Immunol 28(4):211–224
pubmed: 21337903
Matsuoka T, Kobayashi S, Ohashi-Doi K, et al. Immunological changes over three years treatment with Japanese cedar SLIT drops in mono-sensitized and poly-sensitized individuals. Allergol Int. 2022,71(3):405–408
Zhang Y, Luo J, Wang Z et al (2019) Efficacy and safety of sublingual dust mite drops in children with mono- or polysensitized allergic rhinitis. Am J Otolaryngol 40(5):755–760
doi: 10.1016/j.amjoto.2019.07.010
pubmed: 31327579
Cox L, Jacobsen L (2009) Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 103(6):451–460
doi: 10.1016/S1081-1206(10)60259-1
pubmed: 20084837
Lou H, Zhang L (2020) The allergen⁃specific immunotherapy for allergic rhinitis. Chin J Otorhinolaryngol Head Neck Surg 55(5):7